Securing rapid market access for proven medtech innovation in the NHS, delivering it efficiently through the various procurement options – and direct to providers in the case of tariff excluded high-risk devices – and getting it reimbursed adequately, comprises perhaps the most challenging of long-term, complex aims for the health care products industry selling into the UK market.
It is a task that has proved consistently tough for medtech manufacturers. In recent years, companies have improved their engagement...






